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Root extracts of Withania somnifera (Ashwagandha) are commonly used as a remedy for a variety of ailments and a general tonic
for overall health and longevity in the Indian traditional medicine system, Ayurveda. We undertook a study to investigate the
anti-proliferative and diﬀerentiation-inducing activities in the water extract of Ashwagandha leaves (ASH-WEX) by examining in
gliomacells.Preliminarydetection forphytochemicals was performed bythin-layer chromatography. Cytotoxicity was determined
using trypan blue and MTT assays. Expression level of an hsp70 family protein (mortalin), glial cell diﬀerentiation marker
[glial ﬁbrillary acidic protein (GFAP)] and neural cell adhesion molecule (NCAM) were analyzed by immunocytochemistry and
immunoblotting. Anti-migratory assay was also done using wound-scratch assay. Expression levels of mortalin, GFAP and NCAM
showed changes, subsequenttothetreatment with ASH-WEX. Thedatasupporttheexistence ofanti-proliferative,diﬀerentiation-
inducing and anti-migratory/anti-metastasis activities in ASH-WEX that could be used as potentially safe and complimentary
therapy for glioma.
1.Introduction
One of the most versatile plants used in the traditional
Indian medicine system (Ayurveda) is Withania somnifera
(Ashwagandha). It is highly reputed as “Indian ginseng”
and is a member of generally regarded as safe (GRAS)
plants [1]. Extracts from diﬀerent parts of Ashwagandha
have been claimed to promote physical and mental health.
The biologically active constituents of Ashwagandha include
alkaloids, steroidal lactones and saponins [2] that have
been shown to possess neurite outgrowth and anti-cancer
activities [3]. Withanone present in alcoholic extract of
Ashwagandha leaves was shown to selectively kill cancer cells
by activation of tumor suppressor protein p53 [4].
Glioma is highly invasive primary brain tumor that
awaits therapeutics. Extracts of Ashwagandha have been
reported to have inhibitory eﬀects on diﬀerent types of
cancers in animal models and on cell lines [4, 5]. However,
there is very little information on their eﬀect on brain
tumors and tumor-derived cell lines. Since C6 glioma, an N-
nitrosomethyl-urea-induced rat glioma, shows normal glial
cell properties, it has been extensively used as an in vitro glial
model system [6]. We examined the expression of several
proteins including heat shock 70 family protein (mortalin),
immunoglobulin superfamily neural cell adhesion molecule
(NCAM) and an intermediate ﬁlament protein (glial ﬁbril-
lary acidic protein, GFAP) that depicted the proliferative,
tumorigenic, adhesion and diﬀerentiation characteristics [7–
9]i nc o n t r o la n dw a t e re x t r a c to fA s h w a g a n d h al e a v e s
(ASH-WEX)-treated cells. Although mortalin expression
and its subcellular localization showed the proliferative
characteristics of cells, GFAP and NCAM were used as
markers of the diﬀerentiation characteristics including mor-
phogenesis, neural cell diﬀerentiation, axonal outgrowth and
fasciculation [10]. We present the ﬁrst evidence of the anti-
proliferative activity of ASH-WEX that is closely associated
with the induction of senescence and diﬀerentiation in
glioma cells.
2. Methods
2.1. Preparation of ASH-WEX. Dry powder of Ashwagandha
leaves was obtained from the Department of Botanical2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Phase contrast images of C6, U118MG, A172 and YKG1 glioma cells treated with 0.0% (control), 0.5, 1.0 and 2.5% ASH-WEX.
There was signiﬁcant diﬀerence in cell number and morphology in treated groups as compared with the control. ASH-WEX-treated cultures
showed multiple processes and more of diﬀerentiated morphology. Treatment group (2.5%) showed cytotoxic eﬀe c to fA S H - W E Xw i t h
majority dead cells.
and Environmental Sciences, Guru Nanak Dev University,
Amritsar, India, courtesy of Dr A. Nagpal. ASH-WEX was
prepared by suspending 10g of dry leaf powder in 100ml
of distilled water and stirring it overnight at 45 ± 5◦C,
followed by ﬁltration under sterile conditions. The ﬁltrate
thus obtained was treated as 100% ASH-WEX. It was stored
at –20◦C in 1ml aliquots until further use.
2.2. Cell Culture and ASH-WEX Treatments. Rat C6
glioma cell line was obtained from NCCS, Pune, India.
Human glioma cell lines—YKG1, U118MG and A172—
wereobtainedfromHealthScienceResearchResourcesBank,
Japan.ThecelllinesweremaintainedonDulbecco’smodiﬁed
Eagle’s minimal essential medium (DMEM)—supplemented
with streptomycin (100Uml−1), gentamycin (100μgml −1),
10% FCS (Himedia) at 37◦C and humid environment
containing 5% CO2. Cultures at 30–40% conﬂuency were
treated with ASH-WEX (0.1–2.5% diluted in medium) for
72 hours. The medium of control culture was replaced with
af r e s ho n e .
2.3. Chemical Standardization of ASH-WEX and Nature of
Active Components. ASH-WEX was subjected to prelimi-
nary phytochemical screening for alkaloids, amino acids,
anthraquinones, ﬂavonoids, phytosterols, saponins, steroids,
tannins, triterpenoids and reducing sugars following the
methods of Harborne [11] and Kokate [12]. It was fur-
ther subjected to thin-layer chromatography (TLC) using
chloroform:methanol (1:1) as solvent front. TLC plate was
subjected to UV radiation and iodine vapors for observation.
ASH-WEX was also subjected to heat (95◦C), pro-
tein (proteinase K, 1mgml−1 and trypsin 1mgml−1)a n d
nucleotide (DNase I, 100μgml −1; RNase, 100μgml −1) inac-
tivation for 30 minutes each and chilled immediately on ice.
The control samples were kept on ice during the treatments.
These extracts were then tested for anti-proliferative and
diﬀerentiation-inducing activities.
2.4. Proliferation and Cell Membrane Integrity Assays. ASH-
WEX was tested for anti-proliferative activity on C6
glioma cells using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) test. In order to assay
membrane integrity and viability, growth curves were
obtained using trypan blue dye staining method.
2.5.CellularandNuclearMorphologyStudies. Morphological
changes in glioma cells treated with diﬀerent concentrations
of ASH-WEX were examined by phase contrast microscopy,Evidence-Based Complementary and Alternative Medicine 3
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Figure 2: Growth curve inhibition and cytotoxicity assessed by (a) Trypan blue dye uptake assay, (b) MTT assay and (c) Hoechst staining.
Data are representative of three diﬀerent experiments done in triplicates and expressed as mean ± SEM.
and the nuclear morphology was studied using Hoechst
33258 ﬂuorescent microscopy.
2.6. Immunostaining. Cells, control and treated, were ﬁxed
with paraformaldehyde followed by permeabilization with
0.3% Triton-X 100 in phosphate buﬀered saline (PBST).
Cells were incubated with anti-GFAP (1 : 500, Sigma), anti-
mortalin (1:500) [13] and anti-NCAM (1 : 500, Abcys)
antibodies diluted in 0.1% PBST, for 24 hours at 4◦Ci n
humid chamber. Secondary antibody (goat anti-mouse/anti-
rabbit IgG FITC conjugated, from Sigma) was applied for
2 hours at room temperature. Cells were then mounted
withanti-fadingreagentandobserved.Imageswerecaptured
usingCoolSnapCCDcameraandthepictureswereanalyzed
using image pro-plus software version 4.5.1 from the media
cybernetics.
2.7. Protein Assay and Western Blotting. Cells grown and
treated in 90-mm petridishes were harvested with PBS–
EDTA (1mM). Cell pellet was homogenized in buﬀer
(50mM Tris, 150mMNaCl, 1mM EDTA, 100 μMN a V O 4,
1mM PMSF and 0.5mM DTT) and protein content in the
supernatant was determined by the Bradford method.
Protein lysate (20–30μg) was resolved on 10% sodium
dodecyl sulfate-polyacrlylamide gel electrophoresis (SDS-
PAGE) [14] followed by blot transfer onto a PVDF mem-
brane (Hybond-P) using the semidry Novablot system
(Amersham Pharmacia). Subsequently, membranes were
probed with mouse anti-GFAP (1 : 3000), anti-mortalin (1
: 1000) or anti-NCAM (1 : 1000) monoclonal antibodies for
2 hours. Immunoreactive bands were visualized using ECL
Plus western blot detection system (Amersham Biosciences).
In order to account for potential variations in protein
estimation and sample loading, expression of each protein4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of heat and enzymatic treatments on the anti-proliferative activity of ASH-WEX. The ASH-WEX was treated with heat
(95◦C), proteinase K (1mgml−1), trypsin (1mgml−1), DNase I (100μgml −1) and RNase (100μgml −1) for 30 minutes and its anti-
proliferative and diﬀerentiation-inducing activity at concentrations ranging from 0.1 to –2.0% was evaluated in C6 glioma cells. Phase
contrast images of cells (control (a)), and in the presence of heat and enzymatically treated ASH-WEX (c) showed no signiﬁcant diﬀerence
in the cell morphology. MTT assay of control and treated ASH-WEX showed similar anti-proliferative activity (b).
was compared with that of α-tubulin in each sample after
stripping the blot.
2.8. Wound Scratch Assay. In order to investigate C6 cell
migration capability, cells were grown to conﬂuent mono-
layer.Monolayerwaswoundedbyscratchingthesurfacewith
a needle. Following the treatment, the initial wounding and
themovementofcellsinthescratchedareawerephotograph-
ically monitored for 6 hours after the treatment. To evaluate
the correlation between NCAM protein expression and cell
migration capability, cells were immunostained with anti-
NCAM antibody.
2.9.StatisticalAnalysis. Valuesareexpressedasmean ±SEM.
The SigmaStat for Windows (version 3.5) was adopted to
analyze the results by Student’s t-test in order to determine
the signiﬁcance of the means. Values of P < .05 were
considered as statistically signiﬁcant.Evidence-Based Complementary and Alternative Medicine 5
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Figure 4: Analysis of ASH-WEX by TLC. Chloroform:methanol (1
: 1) solvent system revealed seven diﬀerent spots. These spots were
observed under (a) UV light and later visualized using (b) iodine
vapors.
3. Results
3.1. Eﬀect of Ashwagandha ASH-WEX on the Proliferation of
Glioma Cells. Human (YKG1, A172, U118MG) and rat (C6)
glioma cell lines were cultured in the presence of diﬀerent
concentrations of ASH-WEX. At higher concentrations
(>1%) it caused cytotoxicity and cell death (Figure 1). Cells
rounded up in about 48 hours and seemed to undergo
apoptotic cell death. However, at lower concentrations
(≤0.5%), cells appeared to be growth arrested and showed
morphology that appeared similar to the diﬀerentiated cells.
All the cell lines tested showed similar level of killing at
higher concentrations and diﬀerentiation-like phenotype at
lower concentrations. For ease of culture, we focused the
further study on C6 glioma cells. Relationships between
the concentrations of ASH-WEX and their anti-proliferative
eﬀects on C6 glioma cells were further investigated by
MTT assay and manually counting the live and dead cells
with hemocytometer. Cells were treated with ASH-WEX
at concentrations ranging from 0 to 2.5% for 72 hours
and the cell viability was analyzed. ASH-WEX inhibited
the proliferation of C6 glioma cells in a dose-dependent
manner (Figure 2(a)). The extract limited the proliferation
of C6 glioma cells by 5–75% with an IC50 (concentrations
of extracts leading to 50% inhibition of cell growth) of about
1.25% (Figure 2(b)). Cytotoxic eﬀects of the extract on C6
glioma cell line were conﬁrmed by trypan blue dye exclusion
assay.
3.2. ASH-WEX Induces Apoptosis at High Concentration.
When the cells were treated with 0.5 and 1% ASH-WEX we
Table 1: Analysis of phytochemicals in the ASH-WEX.
Phytochemicals ASH-WEX
Flavonoids +
Steroids +
Tannins +
Anthroquinones −
Triterpenoids −
Amino acids +
Saponins +
Phytosterols −
Reducing sugars +
Alkaloids
Hager’s test +
Marqui’s test +
“+”: presence; “−”: absence.
found some cells showing bright, fragmented and condensed
nuclei, membrane blebbing and apoptotic bodies as seen
by Hoechst staining (Figure 2(c)). The data suggested that
these concentrations may induce apoptosis in small fraction
of cell population when the majority of the cells showed
diﬀerentiation-type morphology (Figure 1). Of note, the
control cells were also seen to have some apoptotic cells.
Based on these data, we selected 0.5–1.0% ASH-WEX
for its diﬀerentiation potential for C6 cells, whereas the
concentration >2% caused apoptosis.
3.3. Possible Nature of Bioactive Components of ASH-WEX.
We inactivated ASH-WEX with heat, proteinase K, trypsin,
DNase and RNase and tested its activities. MTT assays and
morphologicalobservations(Figure 3)showednosigniﬁcant
diﬀerence in anti-proliferative or diﬀerentiation-induction
eﬀects between control and the cells treated with these inac-
tivated ASH-WEX preparations. Furthermore, preliminary
screening tests for phytochemicals showed the presence of
ﬂavanoids,steroids,tannins,aminoacids,saponins,reducing
sugarsand alkaloids in ASH-WEX (Table 1). The TLCproﬁle
generatedbymethanol:chloroform(1:1)solventshowedthe
presence of seven spots with Rf values 0.03, 0.20, 0.31, 0.48,
0.70, 0.77 and 0.98 (Figure 4).
3.4. Induction of Diﬀerentiation and Senescence-Like Pheno-
types in Glioma Cells. Human YKG1, A172, U118MG and
rat C6 cell lines when treated with 0.5% of ASH-WEX,
showed morphological changes as shown in Figure 1. They
showed diﬀerentiated morphology with increased number
of processes and enlarged cell size. The cells were growth
inhibited and exhibited stellate process formation indicative
of a more diﬀerentiated astrocytic phenotype. In order
to conﬁrm the occurrence of diﬀerentiation, we examined
the expression of diﬀerentiation marker, GFAP, and found
that the ASH-WEX treatment leads to increased expression
of GFAP (Figure 5). The ASH-WEX-treated cells showed
enhanced GFAP immunoreactivity and were having multiple
processes and enlarged cell size as compared to the control6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: GFAP expression in response to ASH-WEX treatment. (a) Immunoﬂuorescence detection of glial diﬀerentiation marker, GFAP, is
shown in control, ASH-WEX (0.5 and 1.0%)-treated C6 glioma cultures. Images were captured using Nikon E600 ﬂuorescent microscope.
The relative intensity measurement of immunoﬂuorescence is shown (b). Compared with control, signiﬁcant changes were found in ASH-
WEX-treated cells as seen by (b) (P < .02) and (d) (P < .001). (c) Representative western blot hybridization signals for GFAP from control
and test samples (0.5 and 1.0% ASH-WEX-treated). (d) Single cell micrographs of GFAP immunoﬂuorescence in control (i–iii) and 0.5%
ASH-WEX-treated cultures (iv–vi).
cells (Figures 5(a) and 5(d)). Treatment of cells with ASH-
WEX doses >1.0% caused vacuolization in the cytoplasm,
retraction, rounding and detachment of cells from the
surface (Figure 1). Increase in GFAP expression in 0.5 and
1.0% treated cells was also supported by western blotting
results.
Based on the growth arrest induced by ASH-WEX in
glioma cells, we next examined whether its eﬀect caused
induction of senescence in C6 glioma cells. The control and
ASH-WEX-treated cells were stained for mortalin (Figure 6)
that has been previously shown to change the subcellular
localization upon induction of senescence [13]. We foundEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: Mortalin in response to ASH-WEX treatment. (a) Immunoﬂuorescence detection of mortalin is shown in control, 0.5 and 1.0%
ASH-WEX-treated C6 glioma cultures. Images were captured using Nikon E600 ﬂuorescent microscope. (b) Relative intensity measurement
of immunoﬂuorescence. Signiﬁcant change in mortalin expression in response to ASH-WEX-treated cultures compared with control is seen
by (c) (P < .01) and (d) (P < .001). (c) Representative western blot hybridization signals for mortalin from control and test samples (0.5
and 1.0% ASH-WEX-treated cells). Single cell micrographs of mortalin immunoﬂuorescence in control (i–iii) and 0.5% ASH-WEX-treated
(iv–vi) cultures.
that the ASH-WEX-treated cells that attained diﬀerentiated
morphology also showed pancytoplasmic staining typical
of the normal cells. The shift in mortalin staining pattern
occurred in >80% cells treated with low concentration of
ASH-WEX (0.1–0.5%) (Figures 6(a) and 6(d)). The staining
intensity of mortalin was found to be signiﬁcantly increased
in ASH-WEX-treated cells, further conﬁrmed by western
blotting results (Figure 6(c)).
3.5. Change in Cell Adhesion Properties. Since brain tumors
have the characteristics of being highly invasive, we next
examinedtheinvasionpropertyofgliomacellsasconsequent
to the treatment with ASH-WEX. The expression level of cell
adhesion marker NCAM-120 and -140 isoforms signiﬁcantly
increased in cells treated with ASH-WEX, as detected by
both immunostaining and western blot analyses (Figures
7(a), 7(d) and 7(f)). To evaluate the motility of C6 glioma8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: NCAM detection in the presence of ASH-WEX. Immunoﬂuorescence detection of NCAM is shown in control, 0.5 and 1.0% ASH-
WEX-treated C6 glioma cultures (a). Images were captured using Nikon E600 ﬂuorescent microscope. Representative phase contrast images
ofcontrol,0.5or1.0%ASH-WEX-treatedcells,inwhichmotilitywasanalyzedbywound-scratchtest.Imagesshowthestarting(0hoursafter
scratch) and the end (6 hours after scratch) point of the analysis (b). Immunocytochemistry of NCAM analysis performed in both control
and in ASH-WEX-treated cells at 6 hours post wounding (c). Graph showing the relative intensity measurement of immunoﬂuorescence
after 72 hours of treatment with ASH-WEX (d). (e) Graph shows that the rate of C6 glioma migration in response to ASH-WEX treatment
in comparison to untreated cells. Data are obtained from a set of scratch test analysis (N = 3) and are expressed as means ± standard error.
Representative western blot hybridization signals for NCAM from control and test samples (0.5 and 1.0% ASH-WEX treated for 72 hours)
(f). a: (P < .05), b: (P < .02) and d: (P < .001) are signiﬁcant changes in ASH-WEX-treated cultures as compared with control cultures.
cells, we analyzed them in wound healing assay with/without
ASH-WEX. As shown in Figure 7(b), untreated C6 glioma
cells were able to invade the scratched area that was fully
re-colonized by 6 hours. The treatment with 0.5 and 1.0%
water extract strongly reduced the migration rate of the C6
glioma cells. In fact, 6 hours after the scratch, very few
cells were seen in the scratched area in the 1.0% treatment
group (Figure 7(b)). Quantitative analysis also indicated a
signiﬁcant decrease (∼35–75%) in cell migration rate fol-
lowing Ashwagandha treatment (Figure 7(e)). Furthermore,
immunostaining study revealed that all the cells migrating
to the scratched area showed enhanced NCAM expression
in ASH-WEX-treated group as compared with the control
group (Figure 7(c)).
4. Discussion
Glioma is one of the most common primary brain tumors
with only limited options for treatment, and hence calls forEvidence-Based Complementary and Alternative Medicine 9
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Figure 8: Hypothetical diagram summarizing the anti-proliferative, diﬀerentiation- and senescence-inducing, anti-migratory eﬀects of the
ASH-WEX.
the development of novel therapeutic approaches. Alcoholic
extract of Ashwagandha leaves was shown to be selectively
cytotoxic to multiple human cancer cells [4]. Recently,
immune modulatory and apoptosis-inducing properties of
the leaf extract of Ashwagandha have been reported [15, 16].
In the present study, we provide evidence that the ASH-WEX
also has anti-proliferative, diﬀerentiation-inducing and anti-
migratoryactivityforhumanandratgliomacells.Theresults
are summarized in Figure 8 hypothetical diagram. ASH-
WEX has several advantages relating to its feasibility and
ease of preparation, use and consumption as an Ayurvedic
supplement or medicine. We found that the treatment of
C6 glioma, YKG1, U118MG and A172 cells with ASH-WEX
(0.5 and 1.0%) for 72 hours signiﬁcantly inhibited their
proliferation. There was a concentration-dependent decrease
in the cell viability as assessed by trypan blue dye exclusion
analysis and MTT assay with ASH-WEX, concentration
>1.0% being cytotoxic. Thus, ASH-WEX displayed strong
anti-proliferative activity in C6 glioma cells with an IC50
of about 1.25%. Growth inhibition of many human tumor
cell lines, such as human osteogenic sarcoma, ﬁbrosarcoma,
breast carcinoma, lung carcinoma and colon carcinoma and
normal cells has been reported with Ashwagandha extracts
[1]. The anti-proliferative activity of ASH-WEX in human
and rat glioma cells may be the result of inhibition of prolif-
eration and diﬀerentiation of tumor cells as veriﬁed by MTT
test (Figure 2) and enhanced expression of GFAP (Figure 5),
am a r k e ro fg l i a lc e l ld i ﬀerentiation. These results are further
supportedbyphasecontrastimagesofgliomacells(Figure 1)
that show the correlation between the treatment with ASH-
WEX (0.5 and 1.0%) and reduction in the number of cells as
well as their diﬀerentiated morphology.
To evaluate the possible nature of bioactive molecules
in the ASH-WEX, the control and heat, proteinase K,
trypsin, DNase and RNase-treated ASH-WEX were tested
for anti-proliferative activity using MTT assay. There was
no signiﬁcant diﬀerence in the anti-proliferative activity of
the extract after diﬀerent treatments, suggesting that the
active components are neither heat labile, nor proteinecious
and nor nucleic acid in nature. The possibility of the active
molecule being a lipid was also excluded, as ASH-WEX
is aqueous in nature. Earlier studies with the root extract
of Ashwagandha have characterized water-soluble fractions
to contain sitoindosides VII-VIII and withaferin A [17].
Interestingly, withaferin A has been found to be present in
the alcoholic extracts of Ashwagandha leaves [4]. Withaferin
A has been well studied for its tumor-inhibitory potential
bothinvitroandinvivostudies[4,18–20].I tsp r esenc ealo ng
with other possible bioactive components in aqueous leaf
extract is yet to be established by further studies.
The astrocyte marker, GFAP, is involved as a collaborator
inthecomplexcellularprocessescontrollingastrocytomacell
morphology, diﬀerentiation and proliferation [21]. GFAP
was found to be increased in C6 glioma cells following ASH-
WEX treatment, as observed by immunostaining and west-
ern blotting results. C6 cells transfected with GFAP cDNA
showedsigniﬁcantlyreducedtumorgrowth[21].Thegrowth
and invasive potential of the antisense GFAP-transfected
astrocytoma cells was signiﬁcantly enhanced [22]. Some
other studies have also detected marked increase in GFAP
and induction of diﬀerentiation with various diﬀerentiating
agents such as neomycin [23], dimethylformamide [24],
tanshione [25] and retinoic acid [26]. Our data suggested
that the ASH-WEX is able to induce diﬀerentiation in C6
glioma cells, indicating it to be a potential diﬀerentiation-
inducing and anti-cancer agent in glioma. Several recent
studieshavereportedthattheinductionofcellulardiﬀerenti-
ation is an attractive therapeutic strategy against glioma cell
tumorigenicity [27]. These investigations support our cur-
rent results showing the limited proliferation and reversion
of phenotype associated with enhanced GFAP expression in
ASH-WEX-treated cultures. Induction of diﬀerentiation by
ASH-WEX may be further explored as a novel approach in
the multimodality treatment of gliomas.
The diﬀerentiation-inducing potential of ASH-WEX was
further conﬁrmed by immunostaining pattern of mortalin
protein in control and treated cells. Mortalin is distributed
in a pancytoplasmatic manner in normal cells, but in
immortal cells its localization shifts to the perinuclear
zone [13, 28]. In the transformed cells, the reversion of
subcellular distribution of mortalin from perinuclear to
pancytoplasmic type has been reported to correlate with
induction of senescence by introduction of a single chro-
mosome, chromosome-fragments, and genes or chemicals10 Evidence-Based Complementary and Alternative Medicine
[29, 30]. Consistent with these observations, whereas the
control C6 glioma cells showed perinuclear localization of
themortalinprotein,theASH-WEX-treatedculturesshowed
pancytoplasmic localization. The data further indicated that
the glioma cells that undergo diﬀerentiation by ASH-WEX
treatment become non-proliferative. We also found that
there was a signiﬁcantly higher level of mortalin expression
in the 1.0% treated group as compared to the control and
0.5% ASH-WEX treatment group. Such increase in mortalin
may represent a stress response to the ASH-WEX treatment,
an adaptive response. Mechanism and signiﬁcance of such
increase in mortalin in ASH-WEX-treated diﬀerentiated
cells remains to be elucidated. In an earlier study, mortalin
expression was detected in neurons in contrast to the
glial and astrocytes in normal brain tissues [31]. The level
of mortalin expression has been shown to decrease in
Parkinson’s disease (PD) patients signifying that it has a role
in PD [32, 33]. In light of these reports and our data that
mortalin is induced in ASH-WEX-treated glioma cells that
showed diﬀerentiated phenotype, we predict that mortalin
has some novel functions in an induction or maintenance of
neuronal and glial diﬀerentiation. Molecular mechanism(s)
of these functions, their role and signiﬁcance in disease
therapy warrant further studies.
The present data also indicated that the C6 glioma cells
that express NCAM on their cell surface, show reduced
proliferation in response to ASH-WEX treatment. NCAM
has been implicated in cell-cell interaction throughout the
nervous system [34] and is expressed by many tumors of
neuroectodermal origin, including astrocytic tumors [35,
36]. In addition to cell-cell adhesion, homophilic interaction
of NCAM induces signal transduction, resulting in neuronal
diﬀerentiation [37] and inhibition of cell proliferation [38,
39]. Moreover, expression of NCAM has been shown to
reduce migration and invasion of glioma cells in vitro as
well as in vivo [40–42]. Western blot of NCAM in ASH-
WEX-treated C6 glioma cells showed signiﬁcant increase
in the expression of NCAM 140 isoform. Expression of
the transmembrane 140-kDa isoform of NCAM has been
shown to cause signiﬁcant reduction in cellular motility
[43]. The data were further supported in the present anti-
motility assay study in which 1.0% WEX-treated cells were
least motile, whereas control cells migrated to the scratched
area within 6 hours of treatment and covered the scratched
area. Migration can be correlated with in vivo invasiveness
studies. Published evidence indicates that the reduction
in NCAM expression is correlated with increased tumor
invasiveness and overexpressing the transmembrane isoform
NCAM 140 in an invasive NCAM-negative variant of the
glioma inhibited cell invasion [44, 45].
Thus the enhanced expression of GFAP, mortalin and
NCAM in ASH-WEX-treated cells, in the present study, may
suggest the possible mechanism(s) of diﬀerentiation induc-
ing potential of Ashwagandha for the treatment of gliomas.
Similar eﬀects have been observed with alcoholic extract
and its puriﬁed components (Withaferin A, Withanone,
Withanolide A) in C6 glioma cells [20]. Since polysialylated
(PSA)formofNCAMhasbeenimplicatedtofacilitatetumor
invasiveness [46], further studies on its expression pattern
in response to Ashwagandha treatment will be of great
interest.
Although Ashwagandha is most commonly used in
Indian Ayurvedic medicine, the mechanistic aspects of its
eﬀects are still unknown and potential of its bioactive
components are yet to be recognized. Most of the reported
diﬀerentiating agents in glioma (retinoids) are heat-labile
and water insoluble. Thus evaluation and characterization of
the water-soluble active components for discovery of poten-
tially safe glioma-therapeutic phyto-reagents is warranted.
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